Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

Reset IV, LLC dba Reset IV

Has Reset IV received an FDA warning letter? Yes. FDA issued a warning letter dated September 9, 2025 concerning products containing semaglutide and tirzepatide.

Letter facts

Letter date
September 9, 2025 (2025-09-09)
Issuing office
Center for Drug Evaluation and Research (CDER)
Recipient type
Telehealth
Products named
compounded semaglutidecompounded tirzepatide
Violation categories
MisbrandingFalse or misleading claims

Understanding these violation categories

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

False or misleading claims

FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.

Factual Violation Summary

FDA says the website claims compounded semaglutide and tirzepatide are 'the same ingredient in' FDA-approved Wegovy, Ozempic, Zepbound, and Mounjaro, implying unapproved compounded products are FDA-approved, which is false or misleading.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • misbranding - false or misleading labeling (FDCA 502(a))
  • misbranding - false or misleading advertising of compounded drug (FDCA 502(bb))
  • introduction of misbranded drugs into interstate commerce (FDCA 301(a))

More letters about Semaglutide

Recent FDA warning letters concerning Semaglutide:

Similar violations (Misbranding)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.